The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
25 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $13,677,902 in first-year total cost, median $467,621.
Most frequent study sections
- Special Emphasis Panel[ZCA1 RTRB-R (J2)]5
- Special Emphasis Panel[ZCA1 RTRB-U (J1)]5
- Special Emphasis Panel[ZCA1 SRB-K (M2)]4
- Special Emphasis Panel[ZCA1 RTRB-U (M1)]2
- Special Emphasis Panel[ZCA1 SRB-2 (J2)]2
Most frequent institutions
- BECKMAN RESEARCH INSTITUTE/CITY OF HOPE2
- BAYLOR COLLEGE OF MEDICINE1
- BENAROYA RESEARCH INST AT VIRGINIA MASON1
- COLUMBIA UNIVERSITY HEALTH SCIENCES1
- EMORY UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2019 | Precision approaches to refining TP53-associated cancer risk1R01CA242218-01 | AMOS, CHRISTOPHER I.GARBER, JUDY E.WEITZEL, JEFFREY N | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $1,704,138 | ZCA1 |
| 2019 | Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy1R01CA231226-01A1 | BUCKNER, JANE HOYTCHOW, LAURALINSLEY, PETER SWAMBRE, ERIK | BENAROYA RESEARCH INST AT VIRGINIA MASON, WA | $874,780 | ZCA1 |
| 2019 | (PQ3) Integrative biomarkers of cancer progression and therapeutic response from germline and somatic clinical sequencing1R01CA227534-01A1 | BERGER, MICHAEL F. | SLOAN-KETTERING INST CAN RESEARCH, NY | $726,626 | ZCA1 |
| 2019 | (PQ11) Immune modulatory effects of white button mushroom in prostate cancer - A translational research1R01CA227230-01A1 | CHEN, SHIUANLAU, CLAYTONTWARDOWSKI, PRZEMYSLAW WIKTOR | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $689,092 | ZCA1 |
| 2019 | Role of Gut Microbiota in Modulating Immune Checkpoint Inhibitory Therapy for Cancer1R01CA231303-01A1 | HOMSI, JADEKOH, ANDREWPASARE, CHANDRASHEKHAR | UT SOUTHWESTERN MEDICAL CENTER, TX | $627,098 | ZCA1 |
| 2019 | Prevention of paclitaxel-induced peripheral neuropathy with nilotinib1R01CA238946-01 | HU, SHUIYINGLUSTBERG, MARYAM B. | OHIO STATE UNIVERSITY, OH | $624,048 | ZCA1 |
| 2019 | Integrated Informatic and Experimental Evaluations of Cancer Chronotherapy1R01CA227485-01A1 | ANAFI, RON C.HOGENESCH, JOHN B | UNIVERSITY OF PENNSYLVANIA, PA | $594,206 | ZCA1 |
| 2019 | Role of Circadian Factors in Inflammation and Colorectal Adenoma Risk1R01CA231321-01A1 | BURCH, JAMES | UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA, SC | $585,884 | ZCA1 |
| 2019 | (#6) A novel animal model for determining the role of circadian timing in breast cancer development1R01CA231122-01A1 | HELLER, H CRAIG | STANFORD UNIVERSITY, CA | $576,631 | ZCA1 |
| 2019 | Centrosome instability as a mechanism to promote localized prostate cancer1R01CA242226-01 | CRESS, ANNE EROGERS, GREGORY CHARLES | UNIVERSITY OF ARIZONA, AZ | $557,995 | ZCA1 |
| 2019 | (PQ8) Patient- and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibition1R01CA227481-01A1 | BALKO, JUSTIN MJOHNSON, DOUGLAS B | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $538,983 | ZCA1 |
| 2019 | Use of BCL-xL Proteolysis targeting chimeras to treat pancreatic cancer1R01CA242003-01 | TREVINO, JOSE G.ZHENG, GUANGRONGZHOU, DAOHONG | UNIVERSITY OF FLORIDA, FL | $525,664 | ZCA1 |
| 2019 | B cells in autoimmunity following checkpoint blockade therapy1R01CA238471-01 | DHODAPKAR, KAVITA MADHAVSANZ, IGNACIO E. | EMORY UNIVERSITY, GA | $467,621 | ZCA1 |
| 2019 | (PQ7) Defining a new mode of RAS signaling in cancer from cytoplasmic protein granules1R01CA231300-01A1 | BIVONA, TREVER GHUANG, BO | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $454,969 | ZCA1 |
| 2019 | Sympathetic circadian dysfunction in obesity-related hepatocarcinogenesis1R01CA238988-01 | FU, LONING NONEMOORE, DAVID D | BAYLOR COLLEGE OF MEDICINE, TX | $446,883 | ZCA1 |
| 2019 | (PQ5) Microenvironmental Regulation of Mitochondrial Heterogeneity in Cancer Metastasis1R01CA220012-01A1 | SHEN, KEYUE | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $432,614 | ZCA1 |
| 2019 | PQ#12; Targeting Nampt-mediated NAD+ metabolism in chemobrain1R01CA242158-01 | JANG, MI-HYEON | MAYO CLINIC ROCHESTER, MN | $399,247 | ZCA1 |
| 2019 | (PQ2) Donor socioeconomic status as a predictor of altered immune function and treatment response following hematopoietic cell transplantation for hematologic malignancy1R01CA238562-01 | KNIGHT, JENNIFER MARYTURCOTTE, LUCIE MARIE | MEDICAL COLLEGE OF WISCONSIN, WI | $392,698 | ZCA1 |
| 2019 | Developing Tumor-specific PROTACs1R01CA238570-01 | CREWS, CRAIG M | YALE UNIVERSITY, CT | $382,389 | ZCA1 |
| 2019 | Translating Intestinal Radioprotection by EGLN Inhibition to Improve Clinical Outcomes in Unresectable Pancreatic Cancer1R01CA227517-01A1 | TANIGUCHI, CULLEN MITSUO | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $378,555 | ZCA1 |
| 2019 | Germ-line miRNA binding site variants as biomarkers of toxicity and response to checkpoint inhibition1R01CA238998-01 | WEIDHAAS, JOANNE B | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $371,444 | ZCA1 |
| 2019 | Modulating dietary zinc to prevent cachexia and improve survival in cancer1R01CA231239-01A1 | ACHARYYA, SWARNALI | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $370,575 | ZCA1 |
| 2019 | DISCOVERY OF FIRST-IN-CLASS NSD2 DEGRADERS FOR CANCER THERAPY1R01CA242305-01 | JAMES, LINDSEY INGERMAN | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $347,332 | ZCA1 |
| 2019 | Defining how obesity shapes immunity and the success of cancer immunotherapy1R01CA238705-01A1 | TEAGUE, RYAN M | SAINT LOUIS UNIVERSITY, MO | $346,556 | ZCA1 |
| 2019 | PQ3 Cutaneous squamous cell carcinoma: Integrating germline and somatic alterations that underlie tumor progression1R01CA231264-01A1 | ASGARI, MARYAM MANDANA | MASSACHUSETTS GENERAL HOSPITAL, MA | $261,874 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.